Literature DB >> 17605738

Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report.

S Eschertzhuber1, C Velik-Salchner, C Hoermann, D Hoefer, C Lass-Florl.   

Abstract

Invasive aspergillosis (IA) is a severe complication in the post-transplant period in recipients of solid organs. Therefore, early diagnosis and specific therapy of fungal infections in these patients are indispensable. We report the case of a 49-year-old patient, who suffered from IA after cardiac transplantation, which was complicated by post-transplant right heart failure requiring mechanical circulatory support using veno-arterial extracorporeal membrane oxygenation and a right ventricular assist device. Despite antifungal treatment, the patient died 3 weeks after transplantation because of multi-organ failure secondary to IA. The isolated Aspergillus strains exhibited in vitro resistance to caspofungin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17605738     DOI: 10.1111/j.1399-3062.2007.00252.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  9 in total

Review 1.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

2.  Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of Aspergillus species.

Authors:  Joseph Meletiadis; Maria Siopi; Lamprini Kanioura; Karin Meinike Jørgensen; David S Perlin; Johan W Mouton; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

Review 3.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

4.  Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

Authors:  A Espinel-Ingroff; A Fothergill; J Fuller; E Johnson; T Pelaez; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

5.  In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.

Authors:  Michael A Pfaller; Shawn A Messer; Mary R Motyl; Ronald N Jones; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

6.  A multicentre study to optimize echinocandin susceptibility testing of Aspergillus species with the EUCAST methodology and a broth microdilution colorimetric method.

Authors:  Joseph Meletiadis; Maria Siopi; Lamprini Kanioura; Karin Meinike Jørgensen; David S Perlin; Johan W Mouton; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2020-07-01       Impact factor: 5.790

7.  Caspofungin Treatment of Aspergillus fumigatus Results in ChsG-Dependent Upregulation of Chitin Synthesis and the Formation of Chitin-Rich Microcolonies.

Authors:  Louise A Walker; Keunsook K Lee; Carol A Munro; Neil A R Gow
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

8.  Genetic Analysis Using an Isogenic Mating Pair of Aspergillus fumigatus Identifies Azole Resistance Genes and Lack of MAT Locus's Role in Virulence.

Authors:  Liliana Losada; Janyce A Sugui; Michael A Eckhaus; Yun C Chang; Stephanie Mounaud; Abigail Figat; Vinita Joardar; Suman B Pakala; Suchitra Pakala; Pratap Venepally; Natalie Fedorova; William C Nierman; Kyung J Kwon-Chung
Journal:  PLoS Pathog       Date:  2015-04-24       Impact factor: 6.823

9.  Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study.

Authors:  M Winkler; J Pratschke; U Schulz; S Zheng; M Zhang; W Li; M Lu; D Sgarabotto; G Sganga; P Kaskel; S Chandwani; L Ma; J Petrovic; M Shivaprakash
Journal:  Transpl Infect Dis       Date:  2010-01-11       Impact factor: 2.228

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.